Radiopharm Theranostics Ltd ADR (RADX)

NASDAQ
Currency in USD
4.18
-0.23(-5.23%)
Closed·
After Hours
4.47+0.29(+6.94%)
·
RADX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Post-Market activity
Fair Value
Day's Range
4.074.29
52 wk Range
3.5050.82
Key Statistics
Edit
Prev. Close
4.4
Open
4.22
Day's Range
4.07-4.29
52 wk Range
3.5-50.82
Volume
9.31K
Average Volume (3m)
182.08K
1-Year Change
-
Book Value / Share
0.02
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RADX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.19
Upside
+215.46%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year
Show more

Radiopharm Theranostics Ltd ADR Company Profile

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Compare RADX to Peers and Sector

Metrics to compare
RADX
Peers
Sector
Relationship
P/E Ratio
−1.2x−4.6x−0.5x
PEG Ratio
−0.02−0.060.00
Price/Book
1.0x3.1x2.6x
Price / LTM Sales
162.4x8.4x2.9x
Upside (Analyst Target)
198.9%260.0%45.8%
Fair Value Upside
Unlock9.3%8.6%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 13.19
(+215.46% Upside)

Earnings

Latest Release
Feb 28, 2025
EPS / Forecast
-0.01 / --
Revenue / Forecast
2.44M / --
EPS Revisions
Last 90 days

FAQ

What Is the Radiopharm Theranostics ADR (RADX) Stock Price Today?

The Radiopharm Theranostics ADR stock price today is 4.18

What Stock Exchange Does Radiopharm Theranostics ADR Trade On?

Radiopharm Theranostics ADR is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Radiopharm Theranostics ADR?

The stock symbol for Radiopharm Theranostics ADR is "RADX."

What Is the Radiopharm Theranostics ADR Market Cap?

As of today, Radiopharm Theranostics ADR market cap is 34.38M.

What Is Radiopharm Theranostics ADR's Earnings Per Share (TTM)?

The Radiopharm Theranostics ADR EPS (TTM) is -0.04.

When Is the Next Radiopharm Theranostics ADR Earnings Date?

Radiopharm Theranostics ADR will release its next earnings report on 27 May 2025.

From a Technical Analysis Perspective, Is RADX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.